NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Inventiva S.A. (IVA) Stock Analysis

Inventiva S.A. (IVA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IVA

$3.55

+$0.29 (+8.90%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IVA with… →

IVA Key Statistics

As of Oct 21, 2026
Trading
Open
$3.25
Previous Close
$3.26
Day's Range
3.25–3.73
52-Week Range
2.82–7.98
Volume
5.24M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.00
Valuation
Market Cap
$838.58M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
341.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$4.48M−51.26%
Net Income (FY)
−$354.14M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
236.22M
1-Year Return
−31.60%
Dividend and dates
Avg Volume
1.69M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IVA closed at $3.55, −31.60% over 1 year.

Inventiva S.A. (IVA) has a market capitalization of $838.58M.

In fiscal 2025, IVA reported revenue of $4.48M.

IVA Stock Return by Calendar Year

Inventiva S.A. (IVA) return since Jul 2020: what $10,000 became

1 year
$10,000 $6,840
−31.60%
5 years
$10,000 $2,489
−75.11%
Since Jul 2020
$10,000 $2,645
−73.55%

If you had invested $10,000 in Inventiva S.A. (IVA) at the close on July 10, 2020, the earliest close on record here, it would have been worth $2,645 at the close on October 21, 2026: −73.55% in total, −19.08% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−23.66%
2025+117.29%
2024−52.61%
2023+1.26%
2022−67.35%
2021−5.79%
2020 (partial year)+8.05%

As of October 21, 2026.

IVA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.48M−$354.14M−7,899.6%
2024$9.20M−$184.21M−2,002.7%
2023$17.48M−$110.43M−631.8%
2022$12.18M−$54.27M−445.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.48M—−$132.88M−$354.14M−7,899.6%
2024$9.20M—−$93.99M−$184.21M−2,002.7%
2023$17.48M—−$102.67M−$110.43M−631.8%
2022$12.18M—−$56.86M−$54.27M−445.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IVA Valuation vs Biotechnology Median

Median of 608 stocks
MetricIVABiotechnology medianvs median
P/S ratio341.4413.3025.7x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Inventiva S.A. (IVA) is capitalised at $838.58M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 87 employees.

IVA last closed at $3.55 on October 21, 2026. That is +$0.29 (+8.90%) against the previous close. The 52-week range on file runs from $2.82 to $7.98. The latest close sits 25.89% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.48M. Against the prior fiscal year total of $9.20M, that is a change of −51.26%. The same year closed with a net loss of $354.14M. Earnings per share on a trailing basis come to −0.62.

Across the 4 fiscal years on file, revenue moves from $12.18M in 2022 to $4.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 341.44 times revenue. On price-to-sales that is 25.7 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1. Annualized volatility over the trailing 6 years is 77.94%. Over the trailing twelve months the total return is −31.60%. Measured over 5 years, that is −24.28% a year compounded.

Growth & Income

No dividend is on file for IVA.

The strongest complete calendar year on file is 2025 at +117.29%; the weakest is 2022 at −67.35%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −23.66%.

Peer Comparison

Inventiva S.A. (IVA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Inventiva S.A. IVA $838.58M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Inventiva S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Visit website →